Login / Signup

Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.

Lucy HuiGottfried von KeudellRong WangAmer M ZeidanSteven D GoreXiaomei MaAmy J DavidoffScott F Huntington
Published in: Cancer (2017)
BV as consolidation therapy under current US pricing is unlikely to be cost effective at a willingness-to-pay threshold of $100,000 per QALY. However, indication-specific price reductions for the consolidative setting could reduce ICERs to widely acceptable values. Cancer 2017. © 2017 American Cancer Society. Cancer 2017;123:3763-3771. © 2017 American Cancer Society.
Keyphrases
  • papillary thyroid
  • hodgkin lymphoma
  • stem cell transplantation
  • squamous cell
  • squamous cell carcinoma
  • low dose
  • bone marrow
  • childhood cancer
  • young adults
  • mesenchymal stem cells
  • inflammatory response
  • health insurance